Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cinclus Pharma Holding AB ( (SE:CINPHA) ).
Cinclus Pharma Holding AB has announced the initiation of its Phase III HEEALING 1 study to evaluate linaprazan glurate for treating erosive gastroesophageal reflux disease (GERD), following positive regulatory feedback. This study, which will involve approximately 500 patients across seven European countries, aims to demonstrate the drug’s superiority over existing proton pump inhibitors. The company, in partnership with Zentiva, sees significant commercial potential for linaprazan glurate as the first potassium-competitive acid blocker in Europe, with plans to extend development to the US. The strategic partnership with Zentiva includes a licensing agreement valued at EUR 220 million, highlighting the high market demand and potential impact on GERD treatment standards.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing treatments for acid-related diseases and disorders of the upper gastrointestinal tract. Their leading drug candidate, linaprazan glurate, aims to provide more effective healing and symptom relief for gastroesophageal reflux disease (GERD) compared to current treatments.
Average Trading Volume: 72,688
Technical Sentiment Signal: Strong Sell
For an in-depth examination of CINPHA stock, go to TipRanks’ Overview page.